KalVista to Present New Sebetralstat Data at AAAAI 2025 Annual Meeting
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has announced that six of its abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress. This prestigious event is set to take place from February 28 to March 3, 2025, in San Diego, CA. KalVista’s presentations will focus on important data related to the on-demand treatment of hereditary angioedema (HAE) attacks, with a special emphasis on the company’s leading investigational drug, Sebetralstat.
The following presentations will be available on Friday, February 28, 2025, from 2:45–3:45 pm PT in the Convention Center, Ground Level, Hall A:
1. Barriers to Timely On-demand Treatment of Hereditary Angioedema Attacks in Italian Patients (#180): This presentation explores the challenges faced by Italian patients in receiving timely on-demand treatment for HAE attacks. The research, conducted by Mauro Cancian and a team of experts, highlights various barriers that hinder the effectiveness of treatment. The study underscores the need for improvements in patient management and access to timely treatments in the country.
2. Burden of Injectable On-Demand Treatment for Hereditary Angioedema Attacks in Adolescents (#185): Presented by Mauro Cancian, this abstract investigates the burden of injectable on-demand treatments for adolescents suffering from HAE attacks. The research evaluates the impact of current treatment options on this demographic and presents critical insights into how the treatment regimen affects their quality of life, offering potential solutions to improve therapeutic outcomes.
3. Delays in the On-demand Treatment of Hereditary Angioedema Attacks and Associated Barriers Reported in Different Healthcare Systems (#187): This presentation examines the delays in providing on-demand treatment for HAE attacks across various healthcare systems. Authored by Patrick Yong and colleagues, the research highlights systemic barriers that prevent patients from receiving timely treatment, such as accessibility issues, healthcare infrastructure limitations, and regional disparities in medical care.
In addition to these, KalVista will also present late-breaking data on Saturday, March 1, 2025, from 9:45–10:45 am PT in the Convention Center, Ground Level, Hall A:
4. Study to Adjudicate Hereditary Angioedema with Normal C1INH Diagnoses in the PIONEER-HAE Database (#L14): This late-breaking abstract will focus on the PIONEER-HAE database and the study’s efforts to adjudicate hereditary angioedema cases in patients with normal C1INH diagnoses. The research, presented by Maeve O’Connor and the team, sheds light on the complexities of diagnosing HAE with normal C1INH levels, a challenging area for clinicians seeking accurate diagnoses.
5. Effectiveness of Sebetralstat for the On-demand Treatment of Laryngeal Hereditary Angioedema Attacks: Interim Analysis from KONFIDENT-S (#L15): Presented by Jonathan Bernstein and a group of experts, this poster will showcase interim results from the KONFIDENT-S study, focusing on the effectiveness of Sebetralstat in treating laryngeal HAE attacks. Sebetralstat, KalVista’s investigational oral medication, has demonstrated significant promise in treating HAE attacks, and this presentation will highlight its potential in improving outcomes for patients suffering from this life-threatening condition.
Finally, on Saturday, March 1, 2025, from 2:25–2:35 pm PT in the Convention Center, Room 6C, Upper Level, KalVista will provide an oral presentation:
6. On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Adolescents: Pooled Analysis from KONFIDENT and KONFIDENT-S (#552): This oral presentation will delve into the pooled analysis from the KONFIDENT and KONFIDENT-S studies, which assessed the effectiveness of Sebetralstat in treating HAE attacks in adolescents. Presented by Danny Cohn and other key researchers, this presentation will explore the data from both studies to provide an in-depth look at how Sebetralstat can offer significant improvements in the treatment of adolescents with hereditary angioedema.
KalVista Pharmaceuticals is committed to advancing the treatment of HAE, a rare but serious condition characterized by sudden and severe swelling, which can lead to life-threatening complications. Sebetralstat, the company’s oral medication in development, is designed to offer on-demand treatment to manage HAE attacks, and the company’s presentations at AAAAI/WAO 2025 will underscore the potential of this promising new therapy.
“We are pleased to share these important findings with the scientific community at the AAAAI/WAO Joint Congress,” said Dr. Andrew V. Bellinger, Chief Medical Officer at KalVista Pharmaceuticals. “The data we will present further demonstrate the potential of Sebetralstat in transforming how HAE attacks are treated and highlight the significant progress we are making in developing more effective, patient-friendly treatment options for individuals with hereditary angioedema.”
KalVista’s presentations at the AAAAI/WAO 2025 Joint Congress will be an important milestone in the company’s ongoing efforts to bring Sebetralstat and other novel therapies to the market, improving the lives of patients with HAE around the world.
